Apixaban Suitability Assessment and Management

Renal Function Considerations

For patients with severe renal impairment (CrCl <15 mL/min), apixaban should be avoided due to the lack of established safety and efficacy 1
In patients with CrCl 15-29 mL/min, apixaban should be used with extreme caution, as it was not studied in patients with CrCl <25 mL/min 1
Approximately 27% of apixaban undergoes renal elimination, making renal function critical for dosing decisions 1, 3
The American College of Cardiology recommends standard dosing for patients with CrCl ≥30 mL/min 2

For patients with mild hepatic impairment, no significant dose adjustment is needed 3
In patients with moderate hepatic impairment (Child-Pugh B), apixaban exposure is not significantly increased, and it can be used 3
Apixaban is primarily metabolized via CYP3A4-dependent pathways in the liver 1, 3

Combined strong CYP3A4 and P-gp inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) require a 50% reduction in apixaban dose if on 5-10 mg twice daily, and avoidance of combination if on 2.5 mg twice daily 3
Clarithromycin is associated with higher major bleeding rates in retrospective studies 3
Combined strong CYP3A4 and P-gp inducers (e.g., rifampin, carbamazepine, phenytoin) should be avoided due to significantly decreased apixaban exposure and increased thrombotic risk 3

For patients with pancreatic cancer (locally advanced/metastatic), apixaban is recommended for primary VTE prophylaxis in ambulatory patients on systemic therapy with low bleeding risk 2
In patients with intermediate-to-high VTE risk (Khorana score ≥2), apixaban is recommended for ambulatory patients receiving systemic anticancer therapy who are not actively bleeding 2
Apixaban at prophylactic doses can be used as an alternative to LMWH or aspirin in patients with multiple myeloma on immunomodulatory drugs 2

For low bleeding risk procedures, apixaban should be stopped 24 hours before the procedure, and resumed 24 hours after surgery 5
For high bleeding risk procedures, apixaban should be stopped 48 hours before the procedure, and resumed 48-72 hours after surgery at a reduced dose, then increased to full dose 5

Elderly patients (>75 years) require closer monitoring for bleeding complications due to age-related physiological changes, but no routine dose adjustment is needed based solely on age unless combined with other risk factors 6
In hospitalized medically ill patients, DOACs including apixaban are not routinely recommended for VTE prophylaxis, and LMWH, fondaparinux, or unfractionated heparin are preferred 2

Baseline renal function, hepatic function, and complete blood count are required, with periodic reassessment of renal function, especially in elderly or those with declining kidney function 3, 6